Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Targovax ASA ( (GB:0RIS) ) has shared an update.
Circio Holding ASA has announced changes to its upcoming annual general meeting agenda, withdrawing proposals for a reverse share split and share capital decrease. The board has adjusted authorizations to increase share capital, reflecting these withdrawals, which may impact the company’s financial strategy and shareholder interests.
More about Targovax ASA
Circio Holding ASA is a biotechnology company focused on developing advanced RNA technology for nucleic acid medicine. The company has created a unique circular RNA vector expression platform, circVec, which enhances protein expression and is applicable in genetic medicine, cell therapy, and chronic disease treatment. Additionally, Circio is working on a pan-RAS cancer vaccine, TG01, targeting KRAS mutations, with ongoing clinical trials in the USA and Norway.
Average Trading Volume: 1,202,321
Current Market Cap: NOK55.52M
See more data about 0RIS stock on TipRanks’ Stock Analysis page.